664 related articles for article (PubMed ID: 10491431)
21. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
22. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas.
Lamszus K; Laterra J; Westphal M; Rosen EM
Int J Dev Neurosci; 1999; 17(5-6):517-30. PubMed ID: 10571413
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration.
Eckerich C; Zapf S; Fillbrandt R; Loges S; Westphal M; Lamszus K
Int J Cancer; 2007 Jul; 121(2):276-83. PubMed ID: 17372907
[TBL] [Abstract][Full Text] [Related]
25. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
26. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor.
Guerin C; Luddy C; Abounader R; Lal B; Laterra J
Biochem Biophys Res Commun; 2000 Jun; 273(1):287-93. PubMed ID: 10873600
[TBL] [Abstract][Full Text] [Related]
27. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.
Abounader R; Laterra J
Neuro Oncol; 2005 Oct; 7(4):436-51. PubMed ID: 16212809
[TBL] [Abstract][Full Text] [Related]
28. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.
Yu Y; Merlino G
Cancer Res; 2002 May; 62(10):2951-6. PubMed ID: 12019177
[TBL] [Abstract][Full Text] [Related]
29. Met and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour S; Jeffers M; Rulong S; Taylor G; Klineberg E; Hudson EA; Resau JH; Vande Woude GF
Cancer Res; 1997 Dec; 57(23):5391-8. PubMed ID: 9393765
[TBL] [Abstract][Full Text] [Related]
30. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
[TBL] [Abstract][Full Text] [Related]
31. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
32. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
[TBL] [Abstract][Full Text] [Related]
33. Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling.
Lindner G; Menrad A; Gherardi E; Merlino G; Welker P; Handjiski B; Roloff B; Paus R
FASEB J; 2000 Feb; 14(2):319-32. PubMed ID: 10657988
[TBL] [Abstract][Full Text] [Related]
34. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
Jeffers M; Rong S; Anver M; Vande Woude GF
Oncogene; 1996 Aug; 13(4):853-6. PubMed ID: 8761307
[TBL] [Abstract][Full Text] [Related]
35. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
[TBL] [Abstract][Full Text] [Related]
36. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Ried S; Jäger C; Jeffers M; Vande Woude GF; Graeff H; Schmitt M; Lengyel E
J Biol Chem; 1999 Jun; 274(23):16377-86. PubMed ID: 10347197
[TBL] [Abstract][Full Text] [Related]
37. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.
Recio JA; Merlino G
Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907
[TBL] [Abstract][Full Text] [Related]
39. The expression of mRNAs for hepatocyte growth factor/scatter factor, its receptor c-met, and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus.
Thewke DP; Seeds NW
Brain Res; 1999 Mar; 821(2):356-67. PubMed ID: 10064822
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.
Price JA; Kovach SJ; Johnson T; Koniaris LG; Cahill PA; Sitzmann JV; McKillop IH
Hepatology; 2002 Nov; 36(5):1089-97. PubMed ID: 12395318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
